Circulating mRNA Expression of Astrocyte-Elevated Gene-1 Associated with Treatment Response and Survival in Non-Small Cell Lung Cancer Patients Treated with Pemetrexed
Abstract
:1. Introduction
2. Material and Methods
2.1. Patients and Data Collection
2.2. Evaluation of Treatment Responses and Survival
2.3. Isolation of Human PBMCs
2.4. Plasma mRNA Extraction and Quantitative Real-Time PCR
2.5. Statistical Methods
3. Results
3.1. Clinical Evaluation of Treatment Efficacy
3.2. The Association of Plasma Biomarkers and Clinical Treatment Response
3.3. The Elevation of Circulating AEG-1 mRNA Expression Indicated Poor Prognosis
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Ferlay, J.; Soerjomataram, I.; Dikshit, R.; Eser, S.; Mathers, C.; Rebelo, M.; Parkin, D.M.; Forman, D.; Bray, F. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int. J. Cancer 2015, 136, E359–E386. [Google Scholar] [CrossRef]
- Planchard, D.; Popat, S.; Kerr, K.; Novello, S.; Smit, E.F.; Faivre-Finn, C.; Mok, T.S.; Reck, M.; van Schil, P.E.; Hellmann, M.D.; et al. ESMO Guidelines Committee. Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 2018, 29 (Suppl. 4), iv192–iv237. [Google Scholar] [CrossRef]
- Eisenhauer, E.A.; Therasse, P.; Bogaerts, J.; Schwartz, L.H.; Sargent, D.; Ford, R.; Dancey, J.; Arbuck, S.; Gwyther, S.; Mooney, M.; et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur. J. Cancer 2009, 45, 228–247. [Google Scholar] [CrossRef]
- Emdad, L.; Sarkar, D.; Su, Z.Z.; Lee, S.G.; Kang, D.C.; Bruce, J.N.; Volsky, D.J.; Fisher, P.B. Astrocyte elevated gene-1: Recent insights into a novel gene involved in tumor progression, metastasis and neurodegeneration. Pharmacol. Ther. 2007, 114, 155–170. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Hu, G.; Wei, Y.; Kang, Y. The multifaceted role of MTDH/AEG-1 in cancer progression. Clin. Cancer Res. 2009, 15, 5615–5620. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Song, L.; Li, W.; Zhang, H.; Liao, W.; Dai, T.; Yu, C.; Ding, X.; Zhang, L.; Li, J. Over-expression of AEG-1 significantly associates with tumour aggressiveness and poor prognosis in human non-small cell lung cancer. J. Pathol. 2009, 219, 317–326. [Google Scholar] [CrossRef]
- Ke, Z.F.; Mao, X.; Zeng, C.; He, S.; Li, S.; Wang, L.T. AEG-1 expression characteristics in human non-small cell lung cancer and its relationship with apoptosis. Med. Oncol. 2013, 30, 383. [Google Scholar] [CrossRef]
- Zhang, Y.; Li, Z.Y.; Hou, X.X.; Wang, X.; Luo, Y.H.; Ying, Y.P.; Chen, G. Clinical significance and effect of AEG-1 on the proliferation, invasion, and migration of NSCLC: A study based on immunohistochemistry, TCGA, bioinformatics, in vitro and in vivo verification. Oncotarget 2017, 8, 16531–16552. [Google Scholar] [CrossRef] [PubMed]
- Yoo, B.K.; Chen, D.; Su, Z.Z.; Gredler, R.; Yoo, J.; Shah, K.; Fisher, P.B.; Sarkar, D. Molecular mechanism of chemoresistance by Astrocyte Elevated Gene-1 (AEG-1). Cancer Res. 2010, 70, 3249–3258. [Google Scholar] [CrossRef] [Green Version]
- Meng, X.; Thiel, K.W.; Leslie, K.K. Drug resistance mediated by AEG-1/MTDH/LYRIC. Adv. Cancer Res. 2013, 120, 135–157. [Google Scholar]
- Chen, C.Y.; Chen, Y.Y.; Chen, J.J.W.; Chen, K.Y.; Ho, C.C.; Shih, J.Y.; Chang, Y.L.; Yu, C.J.; Yang, P.C. Astrocyte-elevated gene-1 confers resistance to pemetrexed in non-small cell lung cancer by upregulating thymidylate synthase expression. Oncotarget 2017, 8, 61901–61916. [Google Scholar] [CrossRef] [Green Version]
- Alix-Panabières, C.; Pantel, K. Circulating tumor cells: Liquid biopsy of cancer. Clin. Chem. 2013, 59, 110–118. [Google Scholar] [CrossRef] [PubMed]
- Rapisuwon, S.; Vietsch, E.E.; Wellstein, A. Circulating biomarkers to monitor cancer progression and treatment. Comput. Struct. Biotechnol. J. 2016, 14, 211–222. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Garcia, V.; Garcia, J.M.; Pena, C.; Silva, J.; Dominguez, G. Free circulating mRNA in plasma from breast cancer patients and clinical outcome. Cancer Lett. 2008, 263, 312–320. [Google Scholar] [CrossRef] [PubMed]
- Garcia, V.; Garcia, J.M.; Silva, J.; Martin, P.; Pena, C. Extracellular tumor-related mRNA in plasma of lymphoma patients and survival implications. PLoS ONE 2009, 4, e8173. [Google Scholar] [CrossRef] [PubMed]
- March-Villalba, J.A.; Martinez-Jabaloyas, J.M.; Herrero, M.J.; Santamaria, J.; Alino, S.F. Cell-free circulating plasma hTERT mRNA is a useful marker for prostate cancer diagnosis and is associated with poor prognosis tumor characteristics. PLoS ONE 2012, 7, e43470. [Google Scholar] [CrossRef] [Green Version]
- Silva, J.; Garcia, V.; Garcia, J.M.; Pena, C.; Dominguez, G. Circulating Bmi-1 mRNA as a possible prognostic factor for advanced breast cancer patients. Breast Cancer Res. 2007, 9, R55. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Zaporozhchenko, I.A.; Ponomaryova, A.A.; Rykova, E.Y.; Laktionov, P.P. The potential of circulating cell-free RNA as a cancer biomarker: Challenges and opportunities. Expert Rev. Mol. Diagn. 2018, 18, 133–145. [Google Scholar] [CrossRef] [PubMed]
- Levy, B.; Hu, Z.I.; Cordova, K.N.; Close, S.; Lee, K.; Becker, D. Clinical Utility of Liquid Diagnostic Platforms in Non-Small Cell Lung Cancer. Oncologist 2016, 21, 1121–1130. [Google Scholar] [CrossRef] [Green Version]
- Rosell, R.; Cecere, F.; Santarpia, M.; Reguart, N.; Taron, M. Predicting the outcome of chemotherapy for lung cancer. Curr. Opin. Pharmacol. 2006, 6, 323–331. [Google Scholar] [CrossRef]
- Du, Y.J.; Li, J.; Zhu, W.F.; Wu, Y.; Tang, X.P.; Wang, Y.; Hu, Y.M. Survivin mRNA-circulating tumor cells predict treatment efficacy of chemotherapy and survival for advanced non-small cell lung cancer patients. Tumour. Biol. 2014, 35, 4499–4507. [Google Scholar] [CrossRef] [PubMed]
- Gumireddy, K.; Li, A.; Chang, D.H.; Liu, Q.; Kossenkov, A.V.; Yan, J.; Korst, R.J.; Nam, B.T.; Xu, H.; Zhang, L.; et al. AKAP4 is a circulating biomarker for non-small cell lung cancer. Oncotarget 2015, 6, 17637–17647. [Google Scholar] [CrossRef] [Green Version]
- Amin, M.B.; Edge, S.B.; Greene, F.L. AJCC Cancer Staging Manual, 8th ed.; Springer: New York, NY, USA, 2017. [Google Scholar]
- Molina-Vila, M.A.; Mayo-de-Las-Casas, C.; Giménez-Capitán, A.; Jordana-Ariza, N.; Garzón, M.; Balada, A.; Villatoro, S.; Teixidó, C.; García-Peláez, B.; Aguado, C.; et al. Liquid Biopsy in Non-Small Cell Lung Cancer. Front. Med. 2016, 3, 69. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Coco, S.; Alama, A.; Vanni, I.; Fontana, V.; Genova, C.; Dal Bello, M.G.; Truini, A.; Rijavec, E.; Biello, F.; Sini, C.; et al. Circulating Cell-Free DNA and Circulating Tumor Cells as Prognostic and Predictive Biomarkers in Advanced Non-Small Cell Lung Cancer Patients Treated with First-Line Chemotherapy. Int. J. Mol. Sci. 2017, 18, 1035. [Google Scholar] [CrossRef] [Green Version]
- Zhou, J.; Dong, F.; Cui, F.; Xu, R.; Tang, X. The role of circulating tumor cells in evaluation of prognosis and treatment response in advanced non-small-cell lung cancer. Cancer Chemother. Pharmacol. 2017, 79, 825–833. [Google Scholar] [CrossRef] [PubMed]
- Li, H.; Meng, Q.H.; Noh, H.; Batth, I.S.; Somaiah, N.; Torres, K.E.; Xia, X.; Wang, R.; Li, S. Detection of circulating tumor cells from cryopreserved human sarcoma peripheral blood mononuclear cells. Cancer Lett. 2017, 403, 216–223. [Google Scholar] [CrossRef]
- Wang, F.; Li, Y.C.; Liu, L.P.; Zhang, H.M.; Tong, S. Circulating Tumor Cells and Tumor Stem Cells Detection in the Peripheral Blood Mononuclear Cells of Breast Cancer. J. Clin. Lab. Anal. 2016, 30, 616–622. [Google Scholar] [CrossRef] [Green Version]
- Pravin, D.; Potdar Keerti, S. Profiling of circulating tumor cells in liquid biopsies from metastatic cancer patients. J. Cancer Metastasis Treat. 2017, 3, 6–15. [Google Scholar]
- Liu, Y.; Yin, T.J.; Zhou, R.; Zhou, S.; Fan, L.; Zhang, R.G. Expression of thymidylate synthase predicts clinical outcomes of pemetrexed-containing chemotherapy for non-small-cell lung cancer: A systemic review and meta-analysis. Cancer Chemother. Pharmacol. 2013, 72, 1125–1132. [Google Scholar] [CrossRef]
- Wang, T.; Chuan Pan, C.; Rui Yu, J.; Long, Y.; Hong Cai, X.; De Yin, X.; Qiong Hao, L.; Li Luo, L. Association between TYMS expression and efficacy of pemetrexed-based chemotherapy in advanced non-small cell lung cancer: A meta-analysis. PLoS ONE 2013, 8, e74284. [Google Scholar] [CrossRef]
- Nicolson, M.C.; Fennell, D.A.; Ferry, D.; O’Byrne, K.; Shah, R.; Potter, V.; Skailes, G.; Upadhyay, S.; Taylor, P.; André, V.; et al. Thymidylate synthase expression and outcome of patients receiving pemetrexed for advanced nonsquamous non-small-cell lung cancer in a prospective blinded assessment phase II clinical trial. J. Thorac. Oncol. 2013, 8, 930–939. [Google Scholar] [CrossRef] [Green Version]
- Wang, L.; Wang, R.; Pan, Y.; Sun, Y.; Zhang, J.; Chen, H. The pemetrexed-containing treatments in the non-small cell lung cancer is -/low thymidylate synthase expression better than +/high thymidylate synthase expression: A meta-analysis. BMC Cancer 2014, 14, 205. [Google Scholar]
- Christoph, D.C.; Asuncion, B.R.; Hassan, B.; Tran, C.; Maltzman, J.D.; O’Shannessy, D.J.; Wynes, M.W.; Gauler, T.C.; Wohlschlaeger, J.; Hoiczyk, M.; et al. Significance of folate receptor alpha and thymidylate synthase protein expression in patients with non-small-cell lung cancer treated with pemetrexed. J. Thorac. Oncol. 2013, 8, 19–30. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Chamizo, C.; Zazo, S.; Dómine, M.; Cristóbal, I.; García-Foncillas, J.; Rojo, F.; Madoz-Gúrpide, J. Thymidylate synthase expression as a predictive biomarker of pemetrexed sensitivity in advanced non-small cell lung cancer. BMC Pulm. Med. 2015, 15, 132. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Kasai, D.; Ozasa, H.; Oguri, T.; Miyazaki, M.; Uemura, T.; Takakuwa, O.; Kunii, E.; Ohkubo, H.; Maeno, K.; Niimi, A. Thymidylate synthase gene copy number as a predictive marker for response to pemetrexed treatment of lung adenocarcinoma. Anticancer Res. 2013, 33, 1935–1940. [Google Scholar]
- Wang, X.; Wang, Y.; Wang, Y.; Cheng, J.; Wang, Y.; Ha, M. Association of thymidylate synthase gene 3′—untranslated region polymorphism with sensitivity of non-small cell lung cancer to pemetrexed treatment: TS gene polymorphism and pemetrexed sensitivity in NSCLC. J. Biomed. Sci. 2013, 20, 5. [Google Scholar] [CrossRef] [Green Version]
- Pujol, J.L.; Molinier, O.; Ebert, W.; Daures, J.P.; Barlesi, F.; Buccheri, G.; Paesmans, M.; Quoix, E.; Moro-Sibilot, D.; Szturmowicz, M.; et al. CYFRA 21-1 is a prognostic determinant in non-small-cell lung cancer: Results of a meta-analysis in 2063 patients. Br. J. Cancer 2004, 90, 2097–2105. [Google Scholar] [CrossRef]
- Yan, L.; Yao, Y.; Wang, L.H.; Wang, M.L.; Fu, X.H. Detection of CK19, LUNX, and KS1/4 mRNA expression in the peripheral blood for diagnosis of micrometastases in patients with non-small cell lung cancer and their clinical implications. Genet. Mol. Res. 2015, 14, 15090–15095. [Google Scholar] [CrossRef]
- Milaki, G.; Messaritakis, I.; Koinis, F.; Kotsakis, A.; Apostolaki, S.; Dermitzaki, E.K.; Perraki, M.; Hatzidaki, D.; Georgoulias, V. Prognostic value of chemotherapy-resistant CK19 mRNA-positive circulating tumor cells in patients with advanced/metastatic non-small cell lung cancer. Cancer Chemother. Pharmacol. 2017, 80, 101–108. [Google Scholar] [CrossRef]
- Bastawisy, A.E.; Azzouny, M.E.; Mohammed, G.; Allah, A.A.; Behiry, E. Serum cytokeratin 19 fragment in advanced lung cancer: Could we eventually have a serum tumor marker? Ecancermedicalscience 2014, 8, 394. [Google Scholar]
- Bréchot, J.M.; Chevret, S.; Nataf, J.; Le Gall, C.; Frétault, J.; Rochemaure, J.; Chastang, C. Diagnostic and prognostic value of Cyfra 21-1 compared with other tumour markers in patients with non-small cell lung cancer: A prospective study of 116 patients. Eur. J. Cancer 1997, 33, 385–391. [Google Scholar] [CrossRef]
- Emdad, L.; Lee, S.G.; Su, Z.Z.; Jeon, H.Y.; Boukerche, H.; Sarkar, D.; Fisher, P.B. Astrocyte elevated gene-1 (AEG-1) functions as an oncogene and regulates angiogenesis. Proc. Natl. Acad. Sci. USA 2009, 106, 21300–21305. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Ma, Z.; Chen, Y.; Dong, S.; Xu, X.; Liu, J.; Song, P.; Yu, C.; Dai, L. AEG-1 mRNA expression in non-small cell lung cancer is associated with increased tumor angiogenesis. Pathol. Res. Pract. 2017, 213, 1257–1263. [Google Scholar] [CrossRef]
- Ding, Q.; Chen, Y.; Dong, S.; Xu, X.; Liu, J.; Song, P.; Yu, C.; Ma, Z. Astrocyte elevated gene-1 is overexpressed in non-small-cell lung cancer and associated with increased tumour angiogenesis. Interact. Cardiovasc. Thorac. Surg. 2018, 26, 395–401. [Google Scholar] [CrossRef] [PubMed]
Overall | PC (n = 37) | PCB (n = 13) | |
---|---|---|---|
Age, years old, (median, range) | 65 (37–92) | 68 (37–92) | 62 (47–76) |
Gender | |||
Male | 29 (58.0%) | 25 (67.6%) | 4 (30.8%) |
Female | 21 (42.0%) | 12 (32.4%) | 9 (69.2%) |
Smoking status | |||
Current or ever | 21 (42.0%) | 18 (48.6%) | 3 (23.1%) |
Never | 29 (58.0%) | 19 (51.4%) | 10 (76.9%) |
Mutation | |||
EGFR | 22 (44.0%) | 16 (43.2) | 6 (46.2%) |
ALK | 3 (6.0%) | 2 (5.4%) | 1 (7.6%) |
Wild type | 25 (50.0%) | 19 (51.4%) | 6 (46.2%) |
Platinum | |||
Cisplatin | 36 (62.0%) | 28 (75.7%) | 8 (61.5%) |
Carboplatin | 14 (28.0%) | 9 (24.3%) | 5 (38.5%) |
Treatment Response | |||
PR | 26 (52.0%) | 18 (48.6%) | 8 (61.5%) |
SD | 14 (24.0%) | 10 (27.0%) | 4 (30.8%) |
PD | 10 (20.0%) | 9 (24.3%) | 1 (7.7%) |
Response rate (%) | 52% | 48.6% | 61.5% |
Disease control rate (%) | 80% | 75.7% | 92.3% |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Chang, Y.-L.; Chen, Y.-F.; Chen, Y.-Y.; Chang, S.-C.; Chang, C.-Y.; Wei, Y.-F.; Chen, C.-Y. Circulating mRNA Expression of Astrocyte-Elevated Gene-1 Associated with Treatment Response and Survival in Non-Small Cell Lung Cancer Patients Treated with Pemetrexed. Appl. Sci. 2021, 11, 11334. https://doi.org/10.3390/app112311334
Chang Y-L, Chen Y-F, Chen Y-Y, Chang S-C, Chang C-Y, Wei Y-F, Chen C-Y. Circulating mRNA Expression of Astrocyte-Elevated Gene-1 Associated with Treatment Response and Survival in Non-Small Cell Lung Cancer Patients Treated with Pemetrexed. Applied Sciences. 2021; 11(23):11334. https://doi.org/10.3390/app112311334
Chicago/Turabian StyleChang, You-Lung, Yen-Fu Chen, Ying-Yin Chen, Shih-Chieh Chang, Cheng-Yu Chang, Yu-Feng Wei, and Chung-Yu Chen. 2021. "Circulating mRNA Expression of Astrocyte-Elevated Gene-1 Associated with Treatment Response and Survival in Non-Small Cell Lung Cancer Patients Treated with Pemetrexed" Applied Sciences 11, no. 23: 11334. https://doi.org/10.3390/app112311334